Skip to main content
SpringerLink
Log in

Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome

  • Progress in Hematology
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Antiretroviral treatments with highly active antiretroviral therapy (HAART) have shown remarkable progress in the past decade and resulted in impressive improvements in life expectancy and quality of life for patients infected with human immunodeficiency virus 1 (HIV-1). Despite the clinical benefits, the management of HIV infection faces many problems. Although HAART is able to suppress the viral load in the plasma, it is unable to eradicate it, and once HAART is initiated, treatment needs to be continued over a lifetime. The side effects of long-term HAART, such as lipodystrophy, lactic acidosis, insulin resistance, and hyperlipidemia, are negative impacts for patients who receive HAART. In addition, patients need to demonstrate high adherence to the therapy to achieve viral suppression and prevent the development of a drug-resistant virus. This review discusses currently recommended antiretroviral treatment strategies, the difficulties with antiretroviral treatments, and current issues regarding HIV management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Palella FJ {jrJr}, Delaney KM, Moorman AC, et al, for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.

    Article  PubMed  Google Scholar 

  2. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection 2002: updated recommendations of the International AIDS Society — USA panel. JAMA. 2002;288:222–235.

    Article  CAS  PubMed  Google Scholar 

  3. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;36:702–713.

    Article  PubMed  Google Scholar 

  4. Hammer SM, Squires KE, Hughes MD, et al, for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725–733.

    Article  CAS  PubMed  Google Scholar 

  5. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2560–2567.

    Article  CAS  PubMed  Google Scholar 

  6. Hoggs RS, O’Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.

    Article  Google Scholar 

  7. Egger M, May M, Chene G, et al, and the ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.

    Article  PubMed  Google Scholar 

  8. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450–451.

    Article  CAS  PubMed  Google Scholar 

  9. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis. 2005;5:407–414.

    Article  CAS  PubMed  Google Scholar 

  10. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society — USA Panel. JAMA. 2004;292:251–265.

    Article  CAS  PubMed  Google Scholar 

  11. Weidle PJ, Ganea CE, Irwin KL, et al. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis. 2000;181:470–475.

    Article  CAS  PubMed  Google Scholar 

  12. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570–585.

    Article  CAS  PubMed  Google Scholar 

  13. Mandel GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Disease. 6th ed. New York, NY: Churchill Livingstone; 2005:1508.

    Google Scholar 

  14. US Dept of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents — October 6, 2005. Dept of Health and Human Services; 2005. AIDSinfo resources page. US Dept of Health and Human Services Web site. Available at: http://aidsinfo.nih.gov/ContentFiles/Adul-tandAdolescentGL10062005048.pdf. Accessed June 12, 2006.

  15. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2005. The British HIV Association Web site. Available at: http://www.bhiva.org/guidelines/2005/HIV/resis-tancetesting.html. Accessed June 13, 2006.

  16. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609–629.

    Article  PubMed  Google Scholar 

  17. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.

    Article  CAS  PubMed  Google Scholar 

  18. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr. 2002;30:278–287.

    Article  CAS  PubMed  Google Scholar 

  19. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366.

    Article  CAS  PubMed  Google Scholar 

  20. Gallego O, de Mendoza C, Perez-Elias MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS. 2001;15:1701–1706.

    Article  CAS  PubMed  Google Scholar 

  21. O’Brien ME, Clark RAL, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407–414.

    Article  PubMed  Google Scholar 

  22. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603–1614.

    Article  CAS  PubMed  Google Scholar 

  23. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19:979–981.

    Article  CAS  PubMed  Google Scholar 

  24. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.

    Article  CAS  PubMed  Google Scholar 

  25. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999;13:2099–2013.

    Article  CAS  PubMed  Google Scholar 

  26. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34:838–846.

    Article  PubMed  Google Scholar 

  27. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.

    Article  Google Scholar 

  28. Carr A, Samaras K, Thorisdottir A, Kaufman GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–2099.

    Article  CAS  PubMed  Google Scholar 

  29. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med. 2000;133:447–454.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AIDS Clinical Center, International Medical Center of Japan, 1-21-1 Toyama, 162-8655, Shinjuku, Tokyo, Japan

    Miwako Honda & Shinichi Oka

Authors
  1. Miwako Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinichi Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miwako Honda.

About this article

Cite this article

Honda, M., Oka, S. Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Int J Hematol 84, 18–22 (2006). https://doi.org/10.1532/IJH97.06102

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.06102

Key words

Search

Navigation